Supplement to:

Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands

Talitha I. Verhoef[1,2], William K. Redekop[3], Anthonius de Boer[1], Anke-Hilse Maitland-van der Zee[1] on behalf of the EU-PACT group**

[1]Utrecht Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands

[2]Department of Applied Health Research, University College London, United Kingdom

[3]Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

a



b



Figure S1. Percentage time spent in the different INR ranges in the control arm (clinical dosing) for a: phenprocoumon and b: acenocoumarol. Data for the first 3 months was derived from Dutch data of the EU-PACT trial [1] and for months 4-6 and >6 it was derived from the Dutch Federation of Thrombosis Services [2].



a



b

Figure S2. Tornado diagrams showing the influence of effect parameters on the cost-effectiveness ratio of pharmacogenetic dosing versus clinical dosing. a: phenprocoumon, b: acenocoumarol

References

1. Verhoef TI, Ragia G, de Boer A *et al.*: A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. *N. Engl. J. Med.* 369(24), 2304-2312 (2013).

2. : Federation of Dutch Anticoagulant clinics; Samenvatting medische jaarverslagen 2012. Available from: http://www.fnt.nl/media/docs/jaarverslagen/FNT_Medisch_jaarverslag_2012_WEB.pdf.